CTLA4 and B-cell chronic lymphocytic leukemia: For example, a single-arm, open-label clinical trial involving 20 patients with R/R CLL demonstrated that CTLA4 depletion significantly enhanced CAR-T cell activity, achieving an ORR of 70% and a CR rate of 30% with a median PFS of 12 months.